Systemization is key to fulfilling T cell therapy’s promise in cancer

Whilst first generation CAR-T therapies have already transformed cancer treatments, fundamental barriers remain in translating the treatment’s success into solid tumors. The development of CAR-T therapies in this space has primarily been impeded by the lack of novel cancer targets and targeting receptors and scalable and cost-effective manufacturing. The development of next generation T cell therapies, like the emerging TCR-T modality, are able to address these barriers to make personalized T cell immunotherapy scalable and accessible for solid tumor patients worldwide. Recent advances in high-throughput screening, genetic engineering, and automated manufacturing now enable systematic, end-to-end development workflows for targeted T cell therapies and it is evident that further innovation across the entire cell therapy development process is essential to transform extraordinary science into sustainable treatments capable of reaching patients everywhere.

Please enter your email to access content Read now